- Home
- NFBK vs NNNN Comparison
NFBK vs NNNN Comparison
Compare NFBK & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- NNNN
- Stock Information
- Founded
- NFBK 1887
- NNNN 2021
- Country
- NFBK United States
- NNNN Germany
- Employees
- NFBK N/A
- NNNN N/A
- Industry
- NFBK Major Banks
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NFBK Finance
- NNNN Health Care
- Exchange
- NFBK Nasdaq
- NNNN Nasdaq
- Market Cap
- NFBK 406.5M
- NNNN 369.6M
- IPO Year
- NFBK 2007
- NNNN 2025
- Fundamental
- Price
- NFBK $11.32
- NNNN $16.10
- Analyst Decision
- NFBK Buy
- NNNN
- Analyst Count
- NFBK 2
- NNNN 0
- Target Price
- NFBK $13.00
- NNNN N/A
- AVG Volume (30 Days)
- NFBK 189.4K
- NNNN 78.0K
- Earning Date
- NFBK 07-23-2025
- NNNN 01-01-0001
- Dividend Yield
- NFBK 4.62%
- NNNN N/A
- EPS Growth
- NFBK 1.58
- NNNN N/A
- EPS
- NFBK 0.76
- NNNN 0.06
- Revenue
- NFBK $128,407,000.00
- NNNN $8,185,146.00
- Revenue This Year
- NFBK $12.68
- NNNN N/A
- Revenue Next Year
- NFBK $15.15
- NNNN N/A
- P/E Ratio
- NFBK $14.80
- NNNN $286.95
- Revenue Growth
- NFBK N/A
- NNNN 21.95
- 52 Week Low
- NFBK $8.09
- NNNN $5.18
- 52 Week High
- NFBK $14.39
- NNNN $18.50
- Technical
- Relative Strength Index (RSI)
- NFBK 49.05
- NNNN N/A
- Support Level
- NFBK $11.55
- NNNN N/A
- Resistance Level
- NFBK $11.76
- NNNN N/A
- Average True Range (ATR)
- NFBK 0.32
- NNNN 0.00
- MACD
- NFBK -0.07
- NNNN 0.00
- Stochastic Oscillator
- NFBK 41.04
- NNNN 0.00
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.